A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation

A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation
Recruiting
1 years - 99 years
All
1 Location

Brief description of study

In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered with the evening meal or uninterrupted VKA (adjusted to achieve a recommended INR of 2.0 to 3.0). Subjects not randomized to the rivaroxaban arm of the study will be initiated on, transitioned to (if not already on a VKA) or will continue to receive their usual care regimen of uninterrupted VKA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atrial Fibrillation
  • Age: 1 years - 99 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 817681

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.